Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ran Ran, Wenfa Huang, Yaxin Liu, Lin Shao, Xiaoran Liu, Yunyun Niu, Weiyao Kong, Shiping Bo, Hope S Rugo, Sijia Lu & Huiping Li. (2020) Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab. OncoTargets and Therapy 13, pages 4385-4395.
Read now
Read now
Articles from other publishers (18)
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, Sheida Yahyazadeh, Omid Vakili, Yaser Eshaghi Milasi, Vida Veisi, Rohollah Mousavi Dehmordi, Sepideh Asadi, Seyedeh Sara Ghorbanhosseini, Mehdi Rostami, Mina Alimohammadi, Abbas Azadi, Nushin Moussavi, Zatollah Asemi, Azadeh Aminianfar, Hamed Mirzaei & Alireza Mafi. (2023) The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms. Frontiers in Pharmacology 14.
Crossref
Crossref
Qitong Wu & Dipali Sharma. (2023) Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. Cells 12:8, pages 1156.
Crossref
Crossref
Christopher Y.C. Chow, Erich Ferdiansyah Lie, Cheng-Hsun Wu & Louis W.C. Chow. (2022) Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers. Frontiers in Oncology 12.
Crossref
Crossref
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi & Dharmesh M. Patel. (2022) Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines. South Asian Journal of Cancer 11:04, pages 281-286.
Crossref
Crossref
William D. Sinclair & Xiaoyan Cui. (2022) The Effects of HER2 on CDK4/6 Activity in Breast Cancer. Clinical Breast Cancer 22:3, pages e278-e285.
Crossref
Crossref
Alessandro Allegra, Claudia Petrarca, Mario Di Gioacchino, Marco Casciaro, Caterina Musolino & Sebastiano Gangemi. (2022) Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies. Cells 11:7, pages 1128.
Crossref
Crossref
Fahai Chen & Jianmin Fang. (2022) Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Yan Liang, Chao Qian, Yinghong Xie, Xiang Huang, Junjie Chen, Yanlin Ren, Ziyi Fu, Yongfei Li, Tianyu Zeng, Fan Yang, Jianwei Zhou, Wei Li, Yongmei Yin & Changqing Wang. (2021) JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12. Cell Death Discovery 7:1.
Crossref
Crossref
Jong-Ho Cheun, Jiyoung Won, Ji Gwang Jung, Hong-Kyu Kim, Wonshik Han & Han-Byoel Lee. (2021) Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery. Journal of Breast Cancer 24:3, pages 301.
Crossref
Crossref
Mingli Han, Yuanting Gu, Pengwei Lu, Jingyi Li, Hui Cao, Xiangke Li, Xueke Qian, Chao Yu, Yunqing Yang, Xue Yang, Na Han, Dongwei Dou, Jianguo Hu & Huaying Dong. (2020) RETRACTED ARTICLE: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Molecular Cancer 19:1.
Crossref
Crossref
Chundi Gao, Jing Zhuang, Huayao Li, Cun Liu, Chao Zhou, Lijuan Liu, Fubin Feng, Changgang Sun & Jibiao Wu. (2020) Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer. Cancer Cell International 20:1.
Crossref
Crossref
Mingli Han, Xueke Qian, Hui Cao, Fang Wang, Xiangke Li, Na Han, Xue Yang, Yunqing Yang, Dongwei Dou, Jianguo Hu, Wei Wang, Jing Han, Fan Zhang & Huaying Dong. (2020) lncRNA ZNF649-AS1 Induces Trastuzumab Resistance by Promoting ATG5 Expression and Autophagy. Molecular Therapy 28:11, pages 2488-2502.
Crossref
Crossref
Albina Stocker, Andreas Trojan, Constanze Elfgen, Marie-Louis Hilbers, Linda Moskovszky & Zsuzsanna Varga. (2020) Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. Breast Cancer Research and Treatment 183:2, pages 311-319.
Crossref
Crossref
M. Sorokin, K. Ignatev, V. Barbara, U. Vladimirova, A. Muraveva, M. Suntsova, N. Gaifullin, I. Vorotnikov, D. Kamashev, A. Bondarenko, M. Baranova, E. Poddubskaya & A. Buzdin. (2020) Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels. Biochemistry (Moscow) 85:7, pages 758-772.
Crossref
Crossref
Mingli Han, Jianguo Hu, Pengwei Lu, Hui Cao, Chao Yu, Xiangke Li, Xueke Qian, Xue Yang, Yunqing Yang, Na Han, Dongwei Dou, Fan Zhang, Mulin Ye, Changcheng Yang, Yuanting Gu & Huaying Dong. (2020) Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death & Disease 11:1.
Crossref
Crossref
Louis W.C. Chow, Erich F. Lie & Masakazu Toi. 2020. Receptor Tyrosine Kinases. Receptor Tyrosine Kinases
375
428
.
Zhi-Hua Liu, Kun Wang, Dan-Yi Lin, Jie Xu, Jie Chen, Xiao-Yu Long, Yan Ge, Xin-Lan Luo, Ke-Ping Zhang, Yan-Hui Liu & Fang-Ping Xu. (2019) Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases. Breast Cancer Research and Treatment 175:1, pages 51-57.
Crossref
Crossref
Aamir Ahmad. 2019. Breast Cancer Metastasis and Drug Resistance. Breast Cancer Metastasis and Drug Resistance
217
228
.